

The impact of hypertension and use of calcium channel blockers on tuberculosis treatment outcomes

Authors:

Vignesh Chidambaram,¹ Akshay Gupte,² Jann-Yuan Wang,³ Jonathan E. Golub,^{1,4,5} and Petros C. Karakousis^{1,2,5*}

Affiliations:

¹Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

²Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

³Department of Internal Medicine, National Taiwan University Hospital, Taipei; and

⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and

⁵Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

*** Correspondence:**

Petros C. Karakousis, M.D.
Koch Cancer Research Building
1550 Orleans St., Room 110
Baltimore, MD 21287

Phone: 410-502-8233
Email: petros@jhmi.edu

No. of words in abstract: 240

No of words in the text: 3187

No. of words in the introduction: 285

No. of words in the methods: 638

No. of words in the results: 1093

No. of words in the discussion: 1171

Abstract

Background: Hypertension induces systemic inflammation, but its impact on the outcome of infectious diseases like tuberculosis (TB) is unknown. Calcium channel blockers (CCB) improve TB treatment outcomes in pre-clinical models, but their effect in patients with TB remain unclear.

Methods: This retrospective cohort study, including all patients > 18 years receiving treatment for culture-confirmed, drug-sensitive TB from 2000 to 2016 at the National Taiwan University Hospital, assessed the association of hypertension and CCB use with all-cause and infection-related mortality during the first 9 months of TB treatment, as well as sputum-smear microscopy and sputum-culture positivity at 2 and 6 months.

Results: 1052 of the 2894 patients (36.4%) had hypertension. Multivariable analysis revealed that hypertension was associated with increased mortality due to all causes (HR 1.57, 95% confidence interval[CI], 1.23-1.99) and infections (HR 1.87, 95%CI, 1.34-2.6), but there was no statistical difference in microbiological outcomes when stratified based on hypertensive group. Dihydropyridine-CCB (DHP-CCB) use was associated with reduced all-cause mortality (HR 0.67, 95%CI: 0.45-0.98) only by univariate Cox regression. There was no association between DHP-CCB use and infection-related mortality (HR 0.78, 95%CI: 0.46-1.34) or microbiological outcomes in univariate or multivariate regression analyses.

Conclusions: Patients with hypertension have increased all-cause mortality and infection-related mortality during the 9 months following TB treatment initiation. DHP-CCB use may lower all-cause mortality in TB patients with hypertension. The presence of hypertension or the use of CCB did not result in a significant change in microbiological outcomes.

Keywords: Tuberculosis, hypertension, calcium channel blockers, mortality, treatment outcomes

Introduction

Tuberculosis (TB) causes significant mortality worldwide, with approximately 1.5 million TB-related deaths in 2018, and nearly 90% of cases reported in developing countries [1]. Concurrently, the prevalence of hypertension has increased dramatically in many low- and middle-income countries, accounting for nearly 75% of global hypertension cases [2]. There is considerable overlap in countries with high burdens of TB and hypertension [3].

Patients with TB are significantly more likely to have hypertension than controls without TB[4]. Multiple cohort studies have shown an increased risk of cardiovascular and cerebrovascular disease following TB diagnosis [4–6]. Hypertension is associated with systemic inflammation, including increased levels of interleukin (IL)-1, IL-18, and tumor necrosis factor(TNF)- α . Although increased levels of pro-inflammatory mediators are associated with tissue destruction in pre-clinical models [7–9] and higher risk of advanced disease in patients with TB [10,11], the precise effect of hypertension on TB treatment outcomes is unknown.

Calcium channel blockers (CCB) are important first-line drugs used in the treatment of hypertension. Blockade of L-type voltage-gated calcium channels has been shown to improve mycobacterial clearance in preclinical studies [12]. Non-dihydropyridine CCB (non-DHP-CCB), such as verapamil, function as efflux pump inhibitors, decreasing the intrabacillary load in macrophages and increasing the bactericidal activity of bedaquiline against *Mycobacterium tuberculosis* in mouse models [13–16]. In contrast, dihydropyridine CCB (DHP-CCB), such as amlodipine or nifedipine, appear to lack efflux pump inhibitor activity. The effect of CCB use on TB treatment outcomes in humans is unknown.

In the current study, we assessed the impact of hypertension and CCB use on TB treatment outcomes in a retrospective cohort in Taiwan. Specifically, we evaluated the effect of

hypertension and CCB use on 9-month all-cause mortality and infection-related mortality, as well as on sputum-culture positivity during standard treatment for drug-susceptible TB.

Methods

Study design and Population:

We included all adults (aged >18 years) treated for drug-susceptible TB at the National Taiwan University Hospital (NTUH), a tertiary-care hospital situated in Taipei city, from 2000 to 2016. TB diagnosis was established by culture-based detection of *M. tuberculosis* in the sputum using MGIT-960 and Lowenstein–Jensen medium, and repeat sputum cultures were performed at 2 and 6 months after initiating TB treatment [17]. Most patients in this cohort were treated on an outpatient basis according to ATS guidelines [18]. There were no specific exclusion criteria. The study was approved by the institutional review boards at Johns Hopkins University and NTUH. All the data were obtained from the NTUH database.

Baseline Characteristics

Data on age, sex, body mass index (BMI), diabetes mellitus (DM), cancer, chronic kidney disease (CKD), use of hemodialysis, cardiovascular disease, chronic obstructive pulmonary disease (COPD), asthma, liver disease, autoimmune disease, smoking, alcohol abuse, transplantation (both solid organ and bone marrow transplantation), HIV status, baseline sputum smear for acid-fast bacilli (AFB)(0 to 4+), cavitory disease on chest radiography, and prior history of TB were obtained.

Exposures

The two exposures assessed in our study were 1) hypertension and 2) use of CCB among patients with hypertension. We defined hypertension at TB treatment initiation as systolic

blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, according to the Joint National Committee-7 (JNC) and American Heart Association guidelines (2013) [19,20]. A minimum of 2 weeks (14 doses) of the following doses of CCB were taken as the required exposure: DHP-CCB [amlodipine (5mg), felodipine (5mg), lercanidipine (10mg), nifedipine (30mg), nicardipine (60mg)] or non-DHP-CCB [verapamil (240mg) and diltiazem (120 mg)]. CCB exposure was assigned separately for “intention-to-treat” and “per-protocol” analysis. Exposure for the “intention-to-treat” analysis was defined as any CCB use for at least 2 weeks in the first month of TB treatment and for the “per-protocol” analysis as the use of any CCB for $\geq 80\%$ (7.2 months) of the 9-month period following the initiation of TB treatment, or $\geq 80\%$ of the duration of follow-up if lost to follow-up or death occurred before 9 months. In order to appropriately assign CCB exposure, only the patients who survived beyond one month after TB treatment initiation were included for this analysis.

Outcomes

The primary outcomes evaluated were all-cause and infection-related mortality during the first 9 months of TB treatment. The latter was a composite outcome of death due to pneumonia, sepsis, or TB during the first 9 months of TB treatment. Secondary outcomes included sputum-smear positivity and culture-confirmed TB at 2 and 6 months after treatment initiation.

Statistical analysis

Participant characteristics stratified by hypertension and CCB exposure were compared using two-sided t-test and Chi-square test for continuous and categorical variables, respectively. Kaplan-Meier analysis and Cox regression was used to measure the association between the hypertension and all-cause and infection-related mortality in separate models. Person-time at risk of outcome stratified by hypertension status, was calculated from the time of TB

treatment initiation until 9 months, or loss to follow-up or death, whichever occurred first. Sputum-smear and culture positivity at the end of 2 months were analysed using univariate and multivariate logistic regression. Similarly, using separate univariate and multivariate Cox regression models, we measured the association of CCB use, classified according to the “intention-to-treat” and “per-protocol” definitions, and the type of CCB (DHP-CCB or non-DHP-CCB), with all-cause mortality and infection-related mortality. In order to appropriately assign CCB exposure, only patients who survived beyond the first month post-TB treatment initiation were included. Sensitivity analyses were conducted by: i) including patients who died within the first month of TB treatment; and ii) excluding participants who did not receive the required dose of CCB from the comparison group. Potential confounders for multivariate analyses were identified by literature review and exploratory data analysis. Statistical analyses were performed using STATA/IC 16.0 software (StataCorp, College Station, Texas).

RESULTS:

Stratification based on hypertension status

Sociodemographic characteristics and comorbidities of the study participants:

Of the total 2894 culture-confirmed, drug-sensitive pulmonary TB cases, 1052 patients (36.4%) had hypertension (Table 1, Figure 1). The median (IQR) age was 66.6 years (49.1-77.8), with a higher proportion of patients aged ≥ 65 years in the hypertensive group (78.0%) relative to the normotensive group (37.7%) ($p < 0.001$). The hypertensive group had higher percentage of males (72.2% vs 66.0%; $p = 0.862$) and higher median BMI (22.0 vs 20.6; $p = 0.862$) respectively, when compared to the normotensive group. Approximately 40% of the

total patient population were ever-smokers, and 2.8% reported alcoholism, with no statistically significant difference between patients with and without hypertension.

There were higher rates of DM, cardiovascular disease, peripheral vascular disease, cerebrovascular accidents, cancer, CKD, COPD, and cirrhosis among patients in the hypertensive group (Table 2). A greater proportion of patients being smear-positive by microscopy at diagnosis in the normotensive group (45.8%) compared to the hypertensive group (37.4%) ($p<0.001$) (Table 3). A higher percentage of patients in the normotensive group (16.6%) had cavitory disease compared to the hypertensive group (10.3%) ($p<0.001$).

Outcomes

Effect of hypertension on 9-month all-cause mortality

During the first 9 months after TB treatment initiation, there was a significantly higher all-cause mortality in the hypertensive group (290/997 patients, 29.1%) than in the non-hypertensive group (254/1670 patients, 15.2%) ($p<0.001$) (Table 4). The log-rank test of the Kaplan-Meier analysis showed that patients with hypertension had significantly shorter survival compared to patients without hypertension (Figure 2A; $p<0.001$). After adjusting for confounders, patients with hypertension had a HR of 1.57(95%CI 1.23-1.99) for all-cause mortality during TB treatment (Table 5). Other parameters found to be associated with increased 9-month all-cause mortality in the adjusted Cox-regression models were male sex, lower BMI, sputum AFB smear positivity and higher CCI score.

Effect of hypertension on 9-month infection-related mortality

During the first 9 months after TB treatment initiation, a total of 303/2667 patients (11.4%) died of infection-related causes, constituting 55.7% (303/544 patients) of all deaths during the first 9 months of TB treatment (Table 4). Of this group, 43 patients (14.2%) died due to TB-related causes, 124 patients (40.9%) due to pneumonia and 136 patients (44.9%) due to

sepsis. Hypertension was associated with significantly earlier infection-related mortality by the log-rank test of the Kaplan-Meier analysis (Figure 2B; $p < 0.001$). After adjusting for confounders, patients with hypertension had 1.87 times higher hazard of mortality due to infection during TB treatment (95% CI, 1.34–2.61; $P < 0.001$).

Effect of hypertension on microbiological outcomes

Among the 2915 patients included in our study, 265/1640 patients (16.2%) and 6/1551 patients (0.4%) had positive sputum cultures at 2 months and 6 months, respectively. There were no differences among the hypertensive and normotensive groups with respect to the proportion of sputum-culture positivity either at 2 months (16.1% vs 16.2%, respectively; $p=0.862$) or 6 months (0.2% vs 0.6%, respectively; $p=0.216$) (Table 4). Univariate and multivariate models of logistic regression also showed no significant relationship between hypertension and sputum culture or microscopy positivity at 2 months (Supplementary Table 1A).

Stratification based on CCB use

Among the 955 hypertensive patients with follow-up more than 30 days after TB diagnosis, 195 patients (20.4%) received DHP-CCB and 20 patients (2.1%) received non-DHP-CCB, while 5 patients (0.5%) received both DHP-CCB and non-DHP-CCB. Of the 955 patients with hypertension, 54 (5.6%) of these patients were lost to follow up during the first 9 months of treatment. The results of the per-protocol analyses are described in Table 7. Baseline characteristics among CCB users and non-users were not statistically different, except that the CCB use group included a higher percentage of patients with prior TB (13.3% vs 5.2%) ($p < 0.01$).

Stratification of hypertensive patients based on CCB use

Of the total 955 patients with hypertension, 210 patients (77.9%) received the required dose of either CCB type (DHP or non-DHP). Among them, 32/201 patients (16.0%) died of any cause and 29/187 patients (15.4%) died of infection-related causes. Univariate Cox-regression shows a hazard ratio (HR) of 0.68 (95%CI: 0.47-0.99) for all-cause mortality in patients who received any CCB (Table 8). Multivariate analysis after controlling for prior TB history did not yield a significant association with all-cause mortality. Intention-to-treat analysis did not reveal a significant difference in time to all-cause mortality between CCB users and non-users (Supplementary Table 2). Univariate and multivariate analysis did not yield a significant association for infection-related mortality during the first 9 months of TB treatment. Chi-square test (Table 7) and univariate and multivariate logistic regression (Supplementary table 1B) revealed no association between CCB use and microbiological outcomes.

Stratification of hypertensive patients based on non-DHP-CCB use

Twenty patients (1.6%) satisfied the criteria for non-DHP-CCB use. There was no statistically significant difference in all-cause mortality between non-DHP-CCB use (4/15 patients) and CCB non-use (162/704 patients) (26.67% vs 20.79%) ($p=0.852$). Similarly, no statistical difference was found in infection-related mortality between the non-DHP-CCB group (3/15 patients) and non-CCB group (72/704 patients) (20.0% vs 10.80%) ($p=0.314$).

Stratification of hypertensive patients based on DHP-CCB use

As shown in Table 6, there were more male patients ($p=0.03$) and patients with a prior history of TB ($p<0.01$) in patients receiving DHP-CCB compared to those not receiving CCB. Patients receiving DHP-CCB had significantly lower mortality (29/187, 15.2%) compared to those not treated with CCB (162/701, 23.1%; $p=0.02$, Table 7). Kaplan-Meier survival analysis and log-rank test shows that patients treated with DHP-CCB had a significantly

longer survival compared to patients not receiving DHP-CCB (Figure 3A; p-value= 0.041), while multivariate Cox regression did not show a statistically significant relationship to all-cause mortality (Table 8). Intention-to-treat analysis did not reveal a significant difference in time to all-cause mortality between DHP-CCB users and CCB non-users (Supplementary Table 2). There were no statistically significant differences in 9-month infection-related mortality (Figure 3B), or sputum-culture conversion rates at 2 and 6 months of TB treatment among patients with and without DHP-CCB use when chi-square test (Table 7), and univariate and multivariate logistic regression were used (Supplementary Table 1B).

Sensitivity analysis

Sensitivity analysis performed by including patients who died in the first month of TB treatment also showed a lower hazard of all-cause mortality with any CCB use (HR 0.68, 95%CI 0.47-0.99) and DHP-CCB use (HR 0.48, 95%CI 0.33-0.70). However, multivariate Cox regression revealed no significant association with all-cause mortality, and infection-related mortality in patients with hypertension was not found to be associated with CCB use (Supplementary Table 3A). Sensitivity analysis by excluding participants who did not receive a required dose of CCB did not show any significant association with all-cause mortality or infection-related mortality (Supplementary Table 3B).

DISCUSSION

In our cohort of TB patients, 821/1516 patients (54.2%) aged more than 65 years had hypertension. This proportion is considerably higher than that reported previously by Umeki *et al.* in a similar population in Japan (35%) [21]. Of note, most patients with hypertension at the time of TB diagnosis do not report a history of hypertension [22]. Therefore, our findings

would suggest that screening for hypertension is important, especially in elderly patients receiving a new TB diagnosis.

The major finding of our study is that patients with hypertension had a greater adjusted hazard of all-cause mortality (HR 1.57, 95%CI 1.23–1.99) and, interestingly, infection-related mortality (HR 1.87, 95%CI 1.34–2.61) during the first 9 months following initiation of TB treatment. In a prior study by Chiang *et al.*, although hypertension was associated with an increase in the composite outcome of treatment failure, default, and death [23], it was not shown to be an independent predictor of negative outcomes when adjusted for other factors [24]. In that study, death constituted a very small proportion (17.3%) of negative outcomes and a much greater proportion was contributed by treatment default (78.2%) [24]. Our study is the first to show increased short-term mortality attributable to hypertension in patients receiving TB treatment. We found that hypertension was an independent predictor of 9-month all-cause and infection-related mortality, when adjusting for sex, BMI, sputum acid-fast stain at the time of diagnosis, cavitory disease, past history of transplantation, and CCI scores. As age is an important component of CCI, this finding raises the possibility that there could be a direct link connecting hypertension and poor TB treatment outcomes, apart from the age-related co-morbidities frequently observed in patients with hypertension.

Hypertension has long been recognized as an inflammatory condition [25]. Increased levels of C-reactive protein, TNF- α and T-helper cells were observed in patients with hypertension compared to non-hypertensive patients [26,27]. Animal models have shown that decreased levels of renin and angiotensin were associated with decreased levels of peripheral T-lymphocytes and interleukins, such as interleukin IL-1 α , IL-1 β , and IL-6 [28]. Hypertension is also associated with increased oxidative stress [29] and angiotensin II is known to increase the production of reactive oxygen species through nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase [30]. The relationship between NADPH oxidase and ROS with

sepsis-induced mortality has been shown in a mouse model by Kong *et al.* [31]. The higher risk of infection-related mortality seen in hypertensive patients in our study could be due to the increased levels of interleukins, NADPH oxidase, and reactive oxygen species in these patients [32].

While a number of other infections, such as *Aggregatibacter*, *Prevotella* [33], *Helicobacter pylori* [34], HIV [35–37], herpes simplex virus-2 [38], cytomegalovirus [39], *Toxoplasmosis gondii* [40] have been shown to be associated with an increased risk of hypertension, there are no prior studies which assessed the outcome of these infections in the hypertensive patients. In our study, the proportion of patients who had sputum AFB smear positivity and cavitory disease at the time of diagnosis was higher in the non-hypertensive group compared to the hypertensive group, suggesting a higher bacillary burden in the lungs of patients in the former group. However, at 2 and 6 months after TB treatment initiation, there was no statistically significant difference by Chi-square tests and multivariable logistic regression, in rates of sputum AFB smear positivity between the two groups. This suggests that hypertension could interfere with mycobacterial clearance. Other factors associated with worse clinical outcomes at 9 months of TB treatment were the presence of cardiovascular disease, CKD stage ≥ 4 and the presence of cancer. These are consistent with the available evidence from the other retrospective cohort studies performed in patients with TB [17,42].

Blockade of the L-type and R-type voltage-gated calcium channels in macrophages, which are responsible for regulating phagocytic function, have been shown to increase intracellular calcium concentration [12]. This, in turn, has been demonstrated to increase the killing of intracellular mycobacteria in mouse models [12]. Verapamil, a non-DHP-CCB which blocks mycobacterial efflux pumps, has been shown to reduce TB treatment time and decrease the minimum inhibitory concentration of bedaquiline and clofazimine in pre-clinical studies [43]. In addition, verapamil inhibits host cell efflux pumps, and has attracted attention as a

potential host-directed therapy [14,15]. In our study, only 20 patients with hypertension satisfied the criteria for exposure to verapamil and other non-DHP-CCB. Among these patients, there was no significant difference in the 9-month all-cause mortality during TB treatment ($p=0.852$). A clinical trial with a larger sample size of patients receiving non-DHP-CCB is required to further evaluate the potential adjunctive activity of this class of agents in TB treatment. There are no previous studies performed using DHP-CCB as an adjunctive therapy. Our study revealed that DHP-CCB use in hypertensive patients surviving more than 30 days following the initiation of TB treatment was associated with a significant decrease in 9-month all-cause mortality. This finding could not be explained by differences in baseline characteristics between patients receiving and those not receiving DHP-CCB. Interestingly, there was a non-statistically significant trend towards lower sputum AFB positivity rate at 2 months in patients who used DHP-CCB (3.1%) compared to those who did not (6.6%). The culture conversion rates at 2 and 6 months were not statistically significant between the DHP-CCB users and the DHP-CCB non-users.

An important limitation of our study is that sputum smear microscopy and microbiological culture results at 2 months and 6 months post-TB treatment were not available for nearly 25% of the patients in our cohort. There was a drop-out rate of 9%, which could be a source of bias in our study. There were inconsistencies in the reporting of cause of death, which prevented us from accurately assessing TB-specific mortality. The level of control of hypertension and other anti-hypertensive drugs were not obtainable from the available data, which could be confounding factors in study. The availability of precise systolic and diastolic pressure data could permit the evaluation of a possible dose-response curve between these parameters and mortality, as well as CCB blocker efficacy and study outcomes. On the other hand, the large sample size of our cohort enabled the analysis of individual risk factors and their impact on short-term mortality. Additionally, enrolment of all the study participants

from a single centre helped to decrease heterogeneity in the clinical management of these patients.

Our study shows that hypertension is an independent predictor of all-cause mortality during the first 9 months after the initiation of TB treatment after adjustment for sex, BMI, initial sputum AFB smear, history of transplantation and cavitory disease. Also, hypertension was associated with a higher incidence of 9-month infection-related mortality, which included TB-related deaths, pneumonia, and sepsis. Microbiological outcomes were not significantly different between the hypertensive and non-hypertensive groups, despite a higher incidence of smear-positive and cavitory disease in the non-hypertensive group at baseline. The use of DHP-CCB was associated with improved 9-month all-cause mortality in hypertensive patients with TB. Our study highlights the importance of screening for hypertension, especially in elderly patients receiving a new diagnosis of TB. Prospective studies are warranted to determine the potential beneficial effects of controlling hypertension, and specifically use of CCB, on TB treatment outcomes.

REFERENCES

1. WORLD HEALTH ORGANIZATION. GLOBAL TUBERCULOSIS REPORT 2019. S.I.: WORLD HEALTH ORGANIZATION, 2019.
2. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. *Circulation* **2016**; 134:441–450.
3. Seegert AB, Rudolf F, Wejse C, Neupane D. Tuberculosis and hypertension—a systematic review of the literature. *International Journal of Infectious Diseases* **2017**; 56:54–61.
4. Chung W-S, Lin C-L, Hung C-T, et al. Tuberculosis increases the subsequent risk of acute coronary syndrome: a nationwide population-based cohort study. *International Union Against Tuberculosis and Lung Disease*, 2014. Available at: <http://www.ingentaconnect.com/content/iuatld/ijtd/2014/00000018/00000001/art00016#>. Accessed 24 April 2020.
5. Huaman MA, Kryscio RJ, Fichtenbaum CJ, et al. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. *Epidemiol Infect* **2017**; 145:1363–1367.
6. Salindri AD, Wang J-Y, Lin H-H, Magee MJ. Post-tuberculosis incidence of diabetes, myocardial infarction, and stroke: Retrospective cohort analysis of patients formerly treated for tuberculosis in Taiwan, 2002-2013. *Int J Infect Dis* **2019**; 84:127–130.
7. Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. IL-1 β and IL-18: inflammatory markers or mediators of hypertension? *Br J Pharmacol* **2014**; 171:5589–5602.
8. Caillon A, Schiffrin EL. Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence. *Current Hypertension Reports* **2016**; 18. Available at: <http://link.springer.com/10.1007/s11906-016-0628-7>. Accessed 24 April 2020.
9. Kolloli A, Subbian S. Host-Directed Therapeutic Strategies for Tuberculosis. *Front Med* **2017**; 4. Available at: <https://www.frontiersin.org/articles/10.3389/fmed.2017.00171/full>. Accessed 24 April 2020.
10. Yamada G, Shijubo N, Shigehara K, Okamura H, Kurimoto M, Abe S. Increased Levels of Circulating Interleukin-18 in Patients with Advanced Tuberculosis. *American Journal of Respiratory and Critical Care Medicine* **2000**; 161:1786–1789.
11. Sahiratmadja E, Alisjahbana B, de Boer T, et al. Dynamic Changes in Pro- and Anti-Inflammatory Cytokine Profiles and Gamma Interferon Receptor Signaling Integrity Correlate with Tuberculosis Disease Activity and Response to Curative Treatment. *Infection and Immunity* **2007**; 75:820–829.
12. Gupta S, Salam N, Srivastava V, et al. Voltage Gated Calcium Channels Negatively Regulate Protective Immunity to Mycobacterium tuberculosis. *PLOS ONE* **2009**; 4:e5305.
13. Machado D, Pires D, Perdigão J, et al. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis. *PLoS ONE* **2016**; 11:e0149326.

14. Srikrishna G, Gupta S, Dooley KE, Bishai WR. Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment. *Future Microbiology* **2015**; 10:1257–1260.
15. Adams KN, Szumowski JD, Ramakrishnan L. Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-tubercular Drugs. *J Infect Dis* **2014**; 210:456–466.
16. Louw GE, Warren RM, Gey van Pittius NC, et al. Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin-resistant Mycobacterium tuberculosis through Efflux. *Am J Respir Crit Care Med* **2011**; 184:269–276.
17. Chien J-Y, Chen Y-T, Wu S-G, Lee J-J, Wang J-Y, Yu C-J. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. *Clinical Microbiology and Infection* **2015**; 21:59–68.
18. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis* **2016**; 63:e147–e195.
19. Chobanian Aram V., Bakris George L., Black Henry R., et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* **2003**; 42:1206–1252.
20. Jennings Garry L.R., Touyz Rhian M. Hypertension Guidelines. *Hypertension* **2013**; 62:660–665.
21. Umeki S. Clinical Features of Pulmonary Tuberculosis in Young and Elderly Men. *Japanese Journal of Medicine* **1989**; 28:341–347.
22. Whitehouse ER, Perrin N, Levitt N, Hill M, Farley JE. Cardiovascular risk prevalence in South Africans with drug-resistant tuberculosis: a cross-sectional study. *The International Journal of Tuberculosis and Lung Disease* **2019**; 23:587–593.
23. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.313. Geneva, Switzerland: World Health Organization; 2003.
24. Chiang Y-C, Lin Y-M, Lee J-A, Lee C-N, Chen H-Y. Tobacco consumption is a reversible risk factor associated with reduced successful treatment outcomes of anti-tuberculosis therapy. *International Journal of Infectious Diseases* **2012**; 16:e130–e135.
25. McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, Immunity, and Hypertensive End-Organ Damage. *Circ Res* **2015**; 116:1022–1033.
26. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease The ATTICA Study. *Am J Hypertens* **2004**; 17:568–573.
27. Ji Q, Cheng G, Ma N, et al. Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients. *Dis Markers* **2017**; 2017. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516715/>. Accessed 24 June 2020.
28. Xiao L, Kirabo A, Wu J, et al. Renal Denervation Prevents Immune Cell Activation and Renal Inflammation in Angiotensin II-Induced Hypertension. *Circ Res* **2015**; 117:547–557.

29. Crowley SD. The Cooperative Roles of Inflammation and Oxidative Stress in the Pathogenesis of Hypertension. *Antioxid Redox Signal* **2014**; 20:102–120.
30. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. *J Exp Med* **2007**; 204:2449–2460.
31. Kong X, Thimmulappa R, Kombairaju P, Biswal S. NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice. *J Immunol* **2010**; 185:569–577.
32. Miyoshi T, Yamashita K, Arai T, Yamamoto K, Mizugishi K, Uchiyama T. The role of endothelial interleukin-8/NADPH oxidase 1 axis in sepsis. *Immunology* **2010**; 131:331–339.
33. Aoyama N, Suzuki J-I, Kumagai H, et al. Specific periodontopathic bacterial infection affects hypertension in male cardiovascular disease patients. *Heart Vessels* **2018**; 33:198–204.
34. Wan Z, Hu L, Hu M, Lei X, Huang Y, Lv Y. Helicobacter pylori infection and prevalence of high blood pressure among Chinese adults. *J Hum Hypertens* **2018**; 32:158–164.
35. Xu Y, Chen X, Wijayabahu A, et al. Cumulative HIV Viremia Copy-Years and Hypertension in People Living with HIV. *Curr HIV Res* **2020**; 18:143–153.
36. Korem M, Wallach T, Bursztyn M, Maayan S, Olshtain-Pops K. High Prevalence of Hypertension in Ethiopian and Non-Ethiopian HIV-Infected Adults. *Int J Hypertens* **2018**; 2018. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830020/>. Accessed 25 June 2020.
37. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. *Journal of hypertension* **2003**; 21:1377–1382.
38. Sun Y, Pei W, Wu Y, Jing Z, Zhang J, Wang G. Herpes simplex virus type 2 infection is a risk factor for hypertension. *Hypertens Res* **2004**; 27:541–544.
39. Wang Z, Peng X, Li M, et al. Is human cytomegalovirus infection associated with essential hypertension? A meta-analysis of 11,878 participants: Cytomegalovirus and Hypertension. *J Med Virol* **2016**; 88:852–858.
40. Han Y, Nie L, Ye X, et al. The association between Toxoplasma gondii infection and hypertensive disorders in T2DM patients: a case-control study in the Han Chinese population. *Parasitology Research* **2018**; 117:689–695.
41. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. *The Lancet Respiratory Medicine* **2015**; 3:201–209.
42. Igari H, Imasawa T, Noguchi N, et al. Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis. *Journal of Infection and Chemotherapy* **2015**; 21:559–563.
43. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor. *Am J Respir Crit Care Med* **2013**; 188:600–607.

44. National Center for Health Statistics. 2007 National Health Interview Survey (NHIS) Public use data release: NHIS survey description. Division of Health Interview Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention. Available from the NHIS Web site (www.cdc.gov/nchs/nhis.htm). 2008.
45. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* **1987**; 40:373–383.

Figure 1: Flow chart for participant selection




Figure 2A: 9-month survival after TB treatment initiation among patients with (1) and without (0) hypertension.




Figure 2B: Survival analysis for 9-month infection-related mortality after TB treatment initiation among patients with (1) and without (0) hypertension.




Figure 3A: 9-month all-cause mortality following TB treatment initiation among DHP-CCB users




Figure 3B: 9-month infection-related mortality following TB treatment initiation among DHP-CCB users




Table 1: Sociodemographic characteristics of the study participants stratified by hypertension status (N=2894)

Sl. No	Study Characteristics	Measure	Total (n=2894)	Without Hypertension (n=1842)	With Hypertension (n=1052)	p-value
1.	Age (years)	Median (IQR)	66.55 (49.06–77.77)	56.77 (40.56 – 72.67)	75.53 (66.55– 82.43)	<0.001
2.	Age > 65 years	No. (%)	1516 (52.4%)	695 (37.7%)	821 (78.0%)	<0.001
3.	Male sex	No. (%)	1975 (68.2%)	1216 (66.0%)	759 (72.2%)	0.001
4.	BMI	Median (IQR)	21.1 (18.8-23.4)	20.6 (18.5 – 22.7)	22.0 (19.3 – 24.5)	<0.001
5.	Ever-smoker	No. (%)	930 (40.5%)	572 (40.2%)	358 (41.0%)	0.70
6.	Alcoholism	No. (%)	81 (2.8%)	60 (3.3%)	21 (2.0%)	0.05

BMI, body mass index; IQR, interquartile range.

Table 2: Associated co-morbidities of the study participants stratified by hypertension status (N=2894)

Sl. No	Study Characteristics	Measure	Total (n=2894)	Without Hypertension (n=1842)	With Hypertension (n=1052)	p-value
1.	DM	No. (%)	533 (18.5%)	212 (11.5%)	321(30.6%)	<0.001
2.	Cancer	No. (%)	459(15.9%)	238(12.9%)	221(21.1%)	<0.001
3.	CKD stage ≥ 4	No. (%)	128/2513(5.1%)	24/1519(1.6%)	104/994(10.5%)	<0.001
4.	Cardiovascular disease	No. (%)	352 (12.1%)	98 (5.3%)	254 (24.1%)	<0.001
	CAD	No. (%)	291 (10.0%)	81 (4.4%)	210 (19.9%)	<0.001
	AMI	No. (%)	111 (3.8%)	46 (2.5%)	65 (6.2%)	<0.001
	CHF	No. (%)	123 (4.2%)	28 (1.5%)	95 (9.00%)	<0.001
	PVD	No. (%)	83 (2.9%)	28 (1.5%)	55 (5.2%)	<0.001
5.	Asthma	No. (%)	123 (4.2%)	69 (3.7%)	54 (5.1%)	0.07
6.	COPD	No. (%)	451 (15.6%)	223 (12.1%)	228 (21.7%)	<0.001
7.	Bronchiectasis	No. (%)	121 (4.2%)	82 (4.5%)	39 (3.7%)	0.34
8.	Pneumoconiosis	No. (%)	35 (1.2%)	22 (1.2%)	13 (1.2%)	0.92
9.	Autoimmune diseases	No. (%)	115 (4.0%)	64 (3.5%)	51 (4.9%)	0.07
10.	Cirrhosis	No. (%)	50 (1.7%)	29 (1.6%)	21 (2.0%)	0.40
11.	History of transplant	No. (%)	26 (0.9%)	10 (0.5%)	16 (1.5%)	0.007
12.	HIV	No. (%)	65 (2.3%)	54 (2.9%)	11 (1.1%)	0.001
13.	Charlson Comorbidity index	Mean (SD)	3.9 (2.7)	3.0 (2.4)	5.4 (2.4)	<0.001

Abbreviations: AMI, Acute myocardial infarction; CAD, Coronary artery disease; CHF, Congestive Heart failure; CKD, Chronic kidney disease; COPD, Chronic obstructive pulmonary disease; DM, diabetes mellitus; HIV, Human Immunodeficiency Virus; PVD, Peripheral Vascular Disease. *Denominators are mentioned when they are different from the "n"

Table 3: TB disease characteristics of the study participants (N=2894)

Sl. No	Study Characteristics	Measure	Total (n=2894)	Without Hypertension (n=1842)	With Hypertension (n=1052)	p-value
1.	Sputum Smear AFS positive at baseline	No. (%)	1215/2842 (42.8%)	831/1817 (45.8%)	384/1025 (37.4%)	< 0.001
2.	Sputum Smear AFS grade at baseline					<0.001
	0		1627/2842 (57.3%)	986/1817 (54.3%)	641/1029 (39.4%)	
	1+		390/2842 (13.7%)	246/1817 (13.5%)	144/1029 (14.1%)	
	2+		318/2842 (11.2%)	228/1817 (12.6%)	90/1029 (8.8%)	
	3+		241/2842 (8.5%)	164/1817 (9.0%)	77/1029 (7.5%)	
	4+		266/2842 (9.4%)	193/1817 (10.6%)	73/1029 (7.1%)	
3.	Prior TB	No. (%)	98/1598 (6.1%)	65/1040 (6.3%)	33/558 (5.9%)	0.79
4.	Cavity	No. (%)	413 (14.3%)	305 (16.6%)	108 (10.3%)	<0.001

AFS, Acid fast smear. TB, Tuberculosis. *Denominators are mentioned when they are different from the “n”

Table 4: Outcomes in patients with TB stratified by hypertension status (N=2894)

Sl. No	Study Characteristics	Measure	Total (n=2894)	Without Hypertension (n=1842)	With Hypertension (n=1052)	p-value
1.	All-cause mortality within 9 months	No. (%)	544/2667 (20.4%)	254/1670 (15.2%)	290/997 (29.1%)	<0.001
2.	Infection-related mortality within 9 months	No. (%)	303/2667 (11.4%)	135/1670 (8.1%)	168/997 (16.9%)	<0.001
3.	Sputum culture positive at 2 months	No. (%)	265/1640 (16.2%)	165/1020 (16.2%)	100/620 (16.1%)	0.980
4.	Sputum AFB smear positive at 2 months	No. (%)	118/1640 (7.2%)	81/1020 (7.9%)	37/620 (6.0%)	0.13
5.	Sputum culture positive at 6 months	No. (%)	6/1551 (0.4%)	5/978 (0.5%)	1/573 (0.2%)	0.30
6.	Sputum AFB smear positive at 6 months	No. (%)	1/1551 (0.1%)	1/978 (0.1%)	0/573 (0%)	0.44

AFB, Acid fast bacilli. *Denominators are mentioned when they are different from the “n”

Table 5: Crude and adjusted hazard ratios, based on Cox regression model, for all-cause and infection-related mortality during 9 months after initiation of TB treatment (N = 2915)

Characteristic	9-month All-cause Mortality						9-month Infection related mortality					
	Unadjusted HR	(95%CI)	p-value	Adjusted HR [#]	95%CI	p-value	Unadjusted HR	(95%CI)	p-value	Adjusted HR [#]	95%CI	p-value
HTN	2.15	1.81-2.54	<0.001	1.57	1.23 – 1.99	<0.001	2.30	1.83–2.89	<0.001	1.87	1.34–2.61	<0.001
Sex	1.75	1.42 -2.14	<0.001	1.54	1.16 - 2.04	0.003	1.53	1.17–1.99	0.001	1.42	0.98–2.07	0.066
BMI	0.90	0.90-0.96	<0.001	0.90	0.87 - 0.93	<0.001	0.92	0.88–0.96	<0.001	0.89	0.85–0.93	<0.001
Initial AFB	1.03	0.97-1.10	0.294	1.11	1.03 – 1.21	0.008	1.07	0.98–1.16	0.122	1.16	1.04–1.29	0.007
Cavitary disease	1.09	0.87-1.38	0.456	1.27	0.93 – 1.72	0.129	1.12	0.82–1.52	0.496	1.26	0.83–1.92	0.272
History of transplantation	1.47	0.70-3.09	0.344	1.84	0.82 – 4.13	0.141	1.88	0.78–4.55	0.204	2.89	1.18–7.06	0.020
CCI	1.27	1.23-1.31	<0.001	1.25	1.20 - 1.30	<0.001	1.28	1.23–1.33	<0.001	1.25	1.18–1.33	<0.001

Abbreviations: AFB, Acid Fast bacilli; BMI, body mass index; CCI, Charlson co-morbidity index; HTN, hypertension; Initial AFB, Sputum AFB smear at the time of diagnosis.

[#]Adjusted for all the variables in the table

Table 6: Baseline characteristics of participants with hypertension stratified by CCB use (per-protocol) (N=959)

Sl. No	Study Characteristics	Measure	Total (n=959)	All CCB use			DHP-CCB use		
				Without CCB use (n=745)	With CCB use (n=210)	p-value	Without CCB use (n=745)	With DHP-CCB use (n=195)	p-value
1.	Age (years)	Median (IQR)	75.1 (66.4 –82.0)	75.1 (66.2-82.2)	75.0 (67.0-80.8)	0.36	75.1 (66.2-82.2)	74.7 (66.7– 80.6)	0.57
2.	Male Sex	No. (%)	71.94%	73.4%	66.7%	0.05	73.4%	65.6%	0.03
3.	Initial AFB smear	No. (%)	348 (36.7%)	271 (36.6%)	77 (36.8%)	0.95	271 (36.6%)	72 (37.1%)	0.90
5.	Prior TB	No. (%)	32 (6.8%)	19 (5.2%)	13 (13.3%)	<0.01	19 (5.2%)	12 (13.0%)	<0.01
6.	Cavitory disease	No. (%)	98 (10.3%)	75 (10.1%)	23 (11.0%)	0.71	75 (10.1%)	22 (11.3%)	0.62
7.	DM	No. (%)	287 (30.1%)	220 (29.6%)	67 (31.9%)	0.52	220 (29.6%)	62 (31.8%)	0.55
8.	Cancer	No. (%)	194 (20.4%)	153 (20.6%)	41 (19.5%)	0.73	153 (20.6%)	40 (20.5%)	0.98
9.	CKD Stage ≥ 4	No. (%)	85 (9.4%)	65 (9.1%)	20 (10.5%)	0.58	65(9.1%)	19 (10.8%)	0.51
10.	Cardiovascular disease	No. (%)	213(22.2%)	166 (22.2%)	47 (22.3%)	0.98	166(22.2%)	41 (20.9%)	0.63
	CAD		181 (18.9%)	142 (19.0%)	39 (18.5%)	0.87	142(19.0%)	34 (17.4%)	0.61
	AMI		54 (5.6%)	44 (5.9%)	10 (4.7%)	0.53	44(5.9%)	9 (4.6%)	0.48
	CHF		71 (7.4%)	59 (7.9%)	12 (5.7%)	0.28	59(7.9%)	10 (5.1%)	0.18
11.	Asthma	No. (%)	49 (5.1%)	37 (5.0%)	12 (5.7%)	0.67	37(5.0%)	9 (4.6%)	0.84
12.	COPD	No. (%)	214 (22.4%)	157 (21.1%)	57 (27.1%)	0.06	157 (21.1%)	53 (27.2%)	0.07
13.	Bronchiectasis	No. (%)	39 (4.1%)	26 (3.5%)	13 (6.2%)	0.08	26(3.5%)	12 (6.1%)	0.09
14.	Pneumoconiosis	No. (%)	13 (1.4%)	10 (1.3%)	3 (1.4%)	0.93	10(1.3%)	2 (1.0%)	0.73
15.	Autoimmune disease	No. (%)	44 (4.6%)	31 (4.1%)	13 (6.2%)	0.22	31(4.1%)	13 (6.7%)	0.14
16.	Liver cirrhosis	No. (%)	17 (1.8%)	14 (1.8%)	3 (1.5%)	0.66	14(1.8%)	3 (1.5%)	0.75
17.	History of transplant	No. (%)	16 (1.7%)	12 (1.6%)	4 (1.9%)	0.77	12 (1.6%)	4 (2.0%)	0.67
18.	HIV	No. (%)	9 (0.9%)	7 (0.9%)	2 (1.0%)	0.99	7(0.9%)	2 (1.0%)	0.91
19.	CCI	Mean (SD)	5.2 (2.3)	5.2 (2.3)	5.4 (2.1)	0.25	5.2 (2.3)	5.4 (2.1)	0.16

Abbreviations: AFB, Acid Fast bacilli; AMI, Acute myocardial infarction; BMI, body mass index; CAD, Coronary artery disease; CHF, Congestive Heart failure; CKD, Chronic kidney disease; COPD, Chronic obstructive pulmonary disease; DM, diabetes mellitus; HIV, Human Immunodeficiency Virus; MDR-Tb, Multi drug resistant TB

A Ninety-seven patients were excluded from this analysis as they had a follow up time of less than 30 days since TB diagnosis.

Table 7: Outcomes in patients with hypertension stratified by DHP-CCB use (N=2915)

Sl. No	Study Characteristics	Measure	Total (n=959)	All CCB use			DHP-CCB use		
				Without CCB use (n=745)	With CCB use (n=210)	p-value	Without CCB use (n=745)	With DHP-CCB use (n=195)	p-value
1.	All-cause mortality within 9 months	No. (%)	194/905 (21.4%)	162/701 (23.1%)	32/201 (16.0%)	0.03	162/701 (23.1%)	29/187 (15.2%)	0.03
2.	Infection-related mortality within 9 months	No. (%)	106/905 (11.7%)	86/704 (12.3%)	20/201 (10.0%)	0.38	86/704 (12.2%)	18/188 (9.6%)	0.11
3.	Sputum AFB smear positive at 2 months	No. (%)	36/616 (5.8%)	32/474 (6.8%)	4/142 (2.8%)	0.08	32/474 (6.6%)	4/131 (3.1%)	0.11
4.	Sputum AFB smear positive at 6 months	No. (%)	0/569 (0%)	0/443 (0%)	0/126 (0%)	-	0/443 (0%)	0/117 (0%)	-
5.	Sputum culture positive at 2 months	No. (%)	99/616 (16.1%)	75/474 (15.8%)	24/142 (16.8%)	0.76	77/474 (15.8%)	22/131 (16.8%)	0.79
6.	Sputum culture positive at 6 months	No. (%)	1/569 (0.2%)	0/443 (0%)	1/126 (0.2%)	0.59	0/443 (0%)	1/117 (0.2%)	0.607

Abbreviations: AFB, Acid Fast bacilli; CCB, Calcium channel blocker; DHP-CCB, Di-hydropyridine calcium channel blocker.

*Denominators are mentioned when they are different from the "n"

Table 8: Crude and adjusted hazard ratios, based on Cox regression model, for all-cause mortality and infection-related mortality during 9 months after initiation of TB treatment among patients with hypertension and CCB use (per-protocol analysis) (N = 2915)

Characteristic	All-cause mortality						Infection-related mortality					
	Unadjusted HR	(95%CI)	p-value	Adjusted HR [#]	95%CI	p-value	Unadjusted HR	(95%CI)	p-value	Adjusted HR [#]	95%CI	p-value
All CCB												
CCB use	0.68	0.47-0.99	0.04	0.61	0.34-1.10	0.10	0.82	0.49-1.37	0.44	0.70	0.29-1.69	0.43
Old TB	1.35	0.65-2.80	0.43	1.45	0.69-3.01	0.32	2.24	0.87-5.77	0.13	2.37	0.91-6.16	0.08
DHP-CCB												
DHP-CCB use	0.66	0.45-0.98	0.03	0.67	0.37-1.21	0.19	0.78	0.46-1.34	0.38	0.76	0.31-1.85	0.55
Sex	1.24	0.89-1.73	0.19	1.39	0.85-2.28	0.19	1.30	0.80-2.09	0.28	1.22	0.57-2.63	0.59
Old TB	1.35	0.65-2.80	0.43	1.43	0.69-2.97	0.34	2.24	0.87-5.77	0.13	2.35	0.90-6.12	0.08

Abbreviations: CCB, Calcium channel blocker; CI, confidence interval; DHP-CCB, Di-hydropyridine calcium channel blocker; HR, hazard ratio; TB, tuberculosis

[#]Adjusted for all variables included in Table.

[§]Ninety-seven patients were excluded from this analysis as they had a follow up time of less than 30 days since TB diagnosis.